# OnCo record ensartinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ensartinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ensartinib" ;
  schema:name "Ensartinib"@en ;
  schema:description "A Chinese-developed ALK pill approved in the US in December 2024 for first-line ALK-positive lung cancer."@en ;
  schema:url <https://onco.cc/drugs/ensartinib/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Ensartinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q27896019> ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2021.3523>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ensartinib>, <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Small-molecule ALK TKI (second generation)" ;
  schema:alternateName "Ensacove" ;
  onco:approval "CN 2020: ALK-positive NSCLC after crizotinib", "US 2024: ALK-positive locally advanced or metastatic NSCLC, ALK-inhibitor-naive" ;
  onco:related <https://onco.cc/biomarkers/alk-fusion/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/alk-positive-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/alk/> ;
  onco:companies <https://onco.cc/companies/xcovery/>, <https://onco.cc/companies/betta/> ;
  onco:trials <https://onco.cc/trials/nct02767804/>, <https://onco.cc/trials/nct07448116/> .